ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1067

Initiation of Urate-Lowering Therapy in Patients Hospitalized with Gout Flare at a Single Center: Opportunity for Quality Improvement
Abstract Number: 1239

Innovative Patient Empowerment: Evaluating the Effect of a Physician-created Educational Video and To-do Lists on Promoting Preventive Health Measures in Rheumatic Disease Patients
Abstract Number: 1064

Inpatient and Outpatient Palliative Care Referral Practices for Patients with Rheumatic Disease: Retrospective Chart Review at a Single Academic Medical Center
Abstract Number: 1245

Inpatient Discontinuation of Allopurinol – A Quality Improvement (QI) Initiative
Abstract Number: 0733

Inpatient Outcomes in ANCA-Associated Vasculitis: An In-Depth Cross-Sectional Analysis Using NIS Data (2016-2020)
Abstract Number: 0466

Inpatient Outcomes of Rheumatoid Arthritis in Hospitalized Patients Using Cannabis: Data from the National Inpatient Sample
Abstract Number: 1978

Insertional and Midportion Achilles Tendinopathy Have Differences in Presence of Calcifications and Neovascularization
Abstract Number: 0734

Insights into Readmissions of ANCA-Vasculitis Patients: A Nationwide Analysis
Abstract Number: 1922

Insights into Rheumatology Practice in Uganda
Abstract Number: 1819

Insulin-like Growth Factor Binding Protein-7 (IGFBP7) Plays a Pathogenic Role in Dermal Fibrosis and Is Increased in Systemic Sclerosis
Abstract Number: 2643

Integrated Bulk and Single Cell RNA Sequencing Defines Key Pathways Regulating Myofibroblast Differentiation Across ANA Subgroups in Diffuse Systemic Sclerosis
Abstract Number: 0860

Integrated Metabolic and Immunologic Analyses Reveal Distinctive Features of Comorbid Cancer in Patients with Autoimmune Diseases
Abstract Number: 0181

Integrated Multidisciplinary Lupus Social Work Program to Manage Social Determinants of Health in SLE and Lupus Nephritis – Preliminary Results
Abstract Number: 2358

Integration of Single-cell Multi-omics Profiling for Investigating Treatment Response to Tumor Necrosis Factor Alpha Inhibitors in Patients with Axial Spondyloarthritis
Abstract Number: 0271

Intercritical Gout Represents a Systemic Inflammatory State

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].